Ignite Creation Date:
2025-12-25 @ 2:21 AM
Ignite Modification Date:
2026-03-02 @ 5:01 PM
Study NCT ID:
NCT01652534
Status:
TERMINATED
Last Update Posted:
2019-11-13
First Post:
2011-08-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease
Sponsor:
Northwestern University
Organization:
Study Overview
Official Title:
Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease
Status:
TERMINATED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to lack of recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to explore the efficacy of the drug Amantadine for the treatment of freezing of gait in patients with Parkinson's Disease. The investigators hypothesize that amantadine is useful for management of freezing of gait in subjects with Parkinson's Disease.
Detailed Description:
Subjects who meet the eligibility requirements for the study will be randomized to Amantadine versus a matching placebo.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: